Tarsus Pharmaceuticals
TARS
51 hedge funds and large institutions have $222M invested in Tarsus Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 19 reducing their positions, and 1 closing their positions.
800% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 1
19% more funds holding
Funds holding: 43 → 51 (+8)
0.57% more ownership
Funds ownership: 63.22% → 63.79% (+0.57%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $294M → $222M (-$72M)
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.57M |
| 2 |
DAM
DLD Asset Management
New York
|
+$603K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$466K |
| 4 |
CAC
Cowen and Company
New York
|
+$376K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$369K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$31.9M |
| 2 |
JP Morgan Chase
New York
|
-$3.17M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$928K |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$508K |
| 5 |
JG
Jefferies Group
New York
|
-$376K |
TARS Hedge Fund Activity: Q1 2022 in Review
51 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q1 2022, worth a combined $222M — down 24% from $294M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TARS positions and 1 closed out — a net gain of 8 holders — while 11 added to existing stakes and 19 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $5.57M. The largest seller was Frazier Management, exiting entirely with an estimated $31.9M sold.
- 51 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q1 2022, up from 43 in Q4 2021.
- Funds reported $222M of Tarsus Pharmaceuticals stock for Q1 2022, down 24% quarter-over-quarter.
- 9 funds opened new Tarsus Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of +8 holders.
- The largest Tarsus Pharmaceuticals buyer in Q1 2022 was Tang Capital Management, an estimated $5.57M added.
- The largest Tarsus Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $31.9M sold.
Based on aggregated 13F filings for Q1 2022.